| Abstract | We have demonstrated recently the formation of a biologically active metabolite of prostaglandin (PG) E1, 13,14-dihydro-PGE1, during intravenous infusions of PGE1 in patients with peripheral arterial occlusive disease. We have now investigated the levels of the immediate precursor of 13,14-dihydro-PGE1, the biologically inactive 15-keto-13,14-dihydro-PGE1, during intravenous administration of 20 micrograms, 40 micrograms or 80 micrograms PGE1 over a period of 60 min to human volunteers. It was found that levels of 15-keto-13,14-dihydro-PGE1, but not those of PGE1 itself, increased in a dose-dependent manner. Thus, increased formation of 13,14-dihydro-PGE1 from 15-keto-13,14-dihydro-PGE1 with increasing doses of PGE1 can be expected to occur. It remains to be investigated, to which extent formation of small amounts of 13,14-dihydro-PGE1 during intravenous infusion of PGE1 could contribute to the therapeutic effects of PGE1 in patients with peripheral arterial occlusive disease. |
| Authors | B A Peskar, W Cawello, W Rogatti, G Rudofsky
(Affiliation: Department of Pharmacology and Toxicology, Ruhr-University of Bochum, Germany.)
|
| Journal | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
(J Physiol Pharmacol)
Vol. 42
Issue 3
Pg. 327-31
(Sep 1991)
ISSN: 0867-5910 POLAND |
| PMID | 1793892
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- 15-keto-13,14-dihydroprostaglandin E2
- Dinoprostone
- Alprostadil
|
| Topics |
- Adult
- Alprostadil
(blood, pharmacokinetics)
- Dinoprostone
(analogs & derivatives, blood)
- Dose-Response Relationship, Drug
- Humans
- Infusions, Intravenous
- Male
|
